October 26, 2016
Horizon completes acquisition of Raptor
Horizon Pharma has completed the acquisition of Raptor Pharmaceutical…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Business
October 26, 2016
Novartis CEO sees tougher U.S. drug pricing over next three-five years
Novartis expects a more difficult pricing environment for drugs in…
October 25, 2016
Novartis’s Q3 2016 net income $10,9B shorter than last year
Novartis’s Q3 2016 net income $10,9B shorter than last year
October 25, 2016
Allergan completes acquisition of Vitae
Allergan successfully completed its tender offer to purchase …
October 24, 2016
Biophytis outsources AMD drug production to Patheon, USA
Biophytis has entered into an agreement with US firm Patheon for the industrial …
October 21, 2016
Ablynx announces warrant exercise
Ablynx today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 10,050 common shares have been issued by the Company in exchange for EUR47,303 as the result of the exercise of warrants.
October 21, 2016
Premaitha Health issues 940,000 options
Premaitha Health has issued 940,000 options over ordinary shares under the Company’s unapproved share option scheme to two employees.
October 20, 2016
Transgene announces €48 M rights issue, reports €1,1M operating revenue decrease
Transgene, a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the launch and terms of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of circa €48 million, issue premium included (the “Rights Issue”).
October 20, 2016
NCI picks ATCC to distribute tancer models for supporting human cancer models initiative
The National Cancer Institute (NCI) awarded ATCC, a global player in biological materials management and standards, a contract to distribute a new generation of …
October 19, 2016
European Commission approves Shire’s pancreas cancer drug – ONIVYDE
European Commission (EC) has granted Marketing Authorization of ONIVYDE, also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy.